Skip to main content

Table 5 Best Response Rates by cohort.

From: Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer

Cohort

Progressive Disease

Stable Disease

Partial Response

Complete Response

1

3

0

0

0

2

2

1

0

0

3

1

2

0

0

4

5

1

0

0

5

2

0

1

0